In contrast, DUBR was markedly down-regulated in bladder urothelial carcinoma (BLCA), kidney chromophobe (KICH), endocervical adenocarcinoma and cervical squamous cell carcinoma (CESC), lung squamous cell carcinoma (LUSC), lung adenocarcinoma (LUAD), prostate adenocarcinoma (PRAD), ovarian serous cystadenocarcinoma (OV), skin cutaneous melanoma (SKCM), rectum adenocarcinoma (READ), thyroid carcinoma (THCA), testicular germ cell tumors (TGCT), uterine carcinosarcoma (UCS) and uterine corpus endometrial carcinoma (UCEC) (Figure 1). Here, DUBR is linked to ovarian serous cystadenocarcinoma.